touchPODCAST podcast

Overcoming EGFR-TKI resistance: Emerging therapies and biomarker strategies in NSCLC

05/11/2025
0:00
1:06:08
Recuar 15 segundos
Avançar 15 segundos

touchCLINICAL PERSPECTIVES for touchONCOLOGY and touchRESPIRATORY

Module 1: Beyond EGFR: Addressing actionable drug resistance mechanisms

In this module, Professors Jänne and Girard explore the challenges of resistance to EGFR-targeted therapies in non-small cell lung cancer. They discuss how mechanisms such as MET and HER2 amplification drive resistance to first-line osimertinib, review emerging targeted strategies to overcome these barriers, and highlight the importance of biomarker testing and managing treatment side effects when shaping second-line options for patients.

Course director

Prof. Pasi Jänne, Dana-Farber Cancer Institute, Boston, MA, USA

The clinical expert

Prof. Nicholas Girard, Institut Curie, Paris, France

Module 2: Bridging resistance gaps post–EGFR-TKI: Expanding NSCLC treatment beyond actionable targets

In this module, Professor Pasi Jänne and Dr. Helena Yu discuss the evolving management of EGFR-mutant NSCLC after EGFR-TKI progression. They address challenges of unexplained resistance, review combination and ADC treatment approaches, and highlight key factors such as patient selection, safety and emerging biomarkers

Course director

Prof. Pasi Jänne, Dana-Farber Cancer Institute, Boston, MA, USA

The clinical expert

Dr Helena Yu, Memorial Sloan Kettering Cancer Center, New York, NY, USA

This touchPODCAST is for HCPs only.

This activity is funded by an educational grant from AstraZeneca Ltd. 

This medical education is jointly provided by USF Health and touchIME.

touchIME is an EBAC® accredited provider.

For further information visit our website:  

add url

Mais episódios de "touchPODCAST"